Abstract The aim of the study presented here was to evaluate the use of PCR for improving the diagnosis of Toxoplasma gondii infection in immunocompromised hosts. Three hundred thirty-two bronchoalveolar lavage (BAL) fluid samples were analyzed by real-time PCR targeting a 529 bp element of T. gondii. In positive samples, the genotype of the parasite was determined by sequence analysis of the GRA6 gene. Positive results were achieved for 2% (7/332) of the samples tested. Genotyping was possible in two samples and revealed GRA6 type II T. gondii. PCR for detecting T. gondii in BAL samples should be performed in all immunosuppressed HIV-positive patients with symptoms of a systemic infection of unknown etiology. Trimethoprim-sulfamethoxazole prophylaxis does not exclude concomitant infection with T. gondii.
Introduction
The protozoan parasite Toxoplasma gondii is widespread throughout the world from temperate to tropical areas. Infection with T. gondii is mainly seen in three clinical settings where immunosuppression is involved: HIV infection, transplantation and therapy of malignant diseases [1] . Pulmonary infection with T. gondii in the immunocompromised patient is associated with a mortality of 50% [2] . The first reports of T. gondii in immunocompromised patients involved those with leukemia and myeloma [3, 4] , and cerebral toxoplasmosis was recognized early as a particular problem [5] . With the advancements made in transplantation of different organs, especially of the heart [6, 7] and bone marrow [8] and, less often, after kidney transplants, toxoplasmosis in the immunocompromised host has become a well-recognized and serious clinical problem [9] [10] [11] .
The diagnosis of toxoplasmosis in severely immunocompromised patients is difficult to make since the clinical signs of infection are nonspecific and may involve different organs like the central nervous system, the eye, the heart and the lungs [12] . T. gondii can be genetically typed into three main genotypes, i.e. types I, II and III [13] , and it is possible that each genotype may cause a different severity of disease. Analysis of antibodies against the parasite is not useful in immunocompromised patients [14] and the diagnostic procedure in these patients is based on detection of T. gondii-specific nucleic acid. Detection of parasitic DNA is performed using the polymerase chain reaction (PCR).
We used real-time PCR to evaluate if T. gondii DNA can be detected in BAL samples from HIV patients with pulmonary infection of unknown cause. We also performed sequence analysis of the GRA6 gene of T. gondii to determine the genotype of the parasite. Genotyping of T. gondii detected in clinical samples should help in the further evaluation of patients if different clinical manifestations occur, depending on the genotype detected. The clinical records of the patients who tested PCR positive for T. gondii were retrieved in order to identify signs and clinical symptoms indicative of toxoplasmosis, which may help identify which patients would benefit from PCR surveillance.
Materials and methods
A total of 332 bronchoalveolar lavage (BAL) samples from 290 HIV-positive patients attending the Copenhagen University Hospital, Hvidovre HIV cohort were analyzed (ethical approval, 2005/65-31/2, Karolinska University Hospital, Huddinge, Stockholm, Sweden). All patients suffered from advanced HIV disease. The BAL samples were taken after unexplained pulmonary symptoms were observed and were kept at −20°C. Medical records were retrieved for the patients whose BAL samples contained T. gondii DNA.
DNA from BAL samples was extracted using a MagNa pure LC extraction robot (Roche Diagnostics, Mannheim, Germany) according to the instructions of the manufacturer. T. gondii DNA was detected by real-time PCR using a LightCycler 2.0 instrument (Roche Diagnostics). The parasite was detected by amplification and detection of a fragment of a 200-300-fold repeated 529 bp element [15] . Amplification of a 94 bp fragment of this element was performed, and each sample included an internal amplification control [16] . A standard curve was created, based on the assumption that one T. gondii genome is equivalent to 80 fg of DNA [17] . Analysis of tenfold dilution series of T. gondii DNA was performed, and the amount of parasitic genome equivalents in BAL samples was determined using this standard curve.
A fragment of the GRA6 gene was amplified using sense primer 5′ TGT GGT GTT GGC AGT ATC TGT and antisense primer 5′ CCC CTG TTT TCA TCT TTA ATA ATC. PCR was performed using a GeneAmp PCR System 9700 (Applied Biosystems, Stockholm, Sweden). The reaction was incubated for 10 min at 95°C for initial denaturation. Forty cycles of 94°C for 1 min, 55°C for 30 s and 72°C for 1 min, followed by a final extension step at 72°C for 7 min were run. The PCR product was purified using QIAquick PCR Purification Kit (Qiagen, Valencia, CA, USA) and sequence analysis was performed using an ABI 310 Genetic Analyser (Amersham Biosciences, Buckinghamshire, UK). Discrimination of type I, II and III T. gondii was performed by analysis of previously described single nucleotide polymorphisms (SNPs) in the GRA6 gene [18] .
Results and discussion
A total of 332 samples were available from 290 patients. T. gondii-specific DNA corresponding to one genome equivalent or more was found in seven patients (Table 1) . Genotyping using the GRA6 locus was successful in two positive samples, showing the parasites were of type II T. gondii. Records for six of the seven patients could be retrieved (Table 1) . At the time of BAL sampling, the patients had CD4+ T-cell counts between 6 and 130×10 6 per liter with a mean of 39×10 6 per liter, but only one was above 100 at 130×10 6 per liter (normal values are above 650×10 6 per liter). There were no differences in the CD4+ T-cell counts, arterial oxygen partial pressure, PaO 2 , or chest radiographs among the seven T. gondii-positive patients and the remaining cohort (data not shown). Two patients with BAL containing T. gondii DNA had a normal chest radiograph, two showed localized pulmonary infiltrates and two had diffuse, bilateral changes including the only patient with a CD4+ T-cell count above 100. Four patients were also microscopy-positive for Pneumocystis jirovecii. The six patients presented in Table 1 had cough and/or dyspnea and one received oxygen.
All patients received prophylaxis against Pneumocystis; one patient received dapsone and pyrimethamine due to adverse reactions to sulfamethoxazole and trimethoprim and the remaining five patients received sulfamethoxazole and trimethoprim. The patients with the highest amount of T. gondii genome equivalents in the BAL sample received oxygen for hypoxia (Table 1) .
Five patients had Toxoplasma-specific IgG antibodies with both EIA assays and the Sabin Feldman's dye test and one was seronegative; none had Toxoplasma-specific IgM antibodies. Two showed progressive, bilateral pre-retinal exudates compatible with Toxoplasma retinochoroiditis and three patients received treatment for suspected cytomegalovirus infection, including the two patients with retinochoroiditis. One patient had bilateral lymphadenopathy in the groins (Table 1) .
Pulmonary toxoplasmosis is a well-known opportunistic infection in immunocompromised patients [19, 20] and infiltrates of unknown etiology were common in the present cohort. Despite the administration of highly active antiretroviral therapy and prophylaxis with trimethoprim-sulfamethoxazole, T. gondii can cause clinical illness in immunosuppressed patients. Infection with T. gondii in the immunocompromised host is often disseminated with nonspecific symptoms like fever and malaise, and it may involve the brain, eye, liver and lungs. BAL testing is a common diagnostic procedure in immunocompromised patients with pulmonary infiltrates of unknown origin.
By monitoring bone marrow transplant (BMT) patients with PCR testing of peripheral blood, BAL fluid and CSF (according to local symptoms), treatment has reduced mortality to the levels seen in BMT patients not infected with T. gondii [21] . Analysis of BAL material in immunocompromised HIV-positive patients should include PCR for toxoplasmosis [12] .
The medical records for the six patients with BAL containing T. gondii DNA, showed the patients had multiple clinical symptoms, but all had pulmonary symptoms of cough or dyspnea (Table 1) . Toxoplasma-specific IgG-antibodies were found in five of the six patients. This was expected, since only a small proportion of immunosuppressed HIV-positive patients with T. gondii infection are seronegative [22] .
In the present study GRA6 sequence analysis was used to determine the genotype of the parasite, and it was successful in two BAL samples containing more than ten parasitic genome equivalents. Due to the lower sensitivity of the genotyping method compared with that of the realtime PCR assay targeting the 529 bp element, genotyping failed in the remaining BAL samples containing T. gondii DNA. Successful genotyping revealed GRA6 type II T. gondii. The patient with the highest number of T. gondii genome equivalents in BAL was the only patient receiving oxygen for hypoxia, and it is tempting to speculate that the pulmonary GRA6 type II T. gondii infection contributed to the reduced pulmonary function. A previous study of T. gondii isolated from Danish domesticated animals also found type II strains exclusively [23] . The source of infection remains unknown, but intake of contaminated food has been shown to be the most important source of human infections in Europe [24] .
In patients receiving a heart transplant, it has been shown that prophylaxis with pyrimethamine has been very effective in preventing clinical toxoplasmosis [25] , and further studies found that trimethoprim-sulfamethoxazole prophylaxis for P. jirovecii was equally effective [26] . Trimethoprim-sulfamethoxazole prophylaxis for P. jirovecii also reduced the risk of clinical T. gondii infection in HIV patients [27] [28] [29] . Nevertheless, the results reported here indicate that prophylaxis against P. jirovecii with trimethoprim-sulfamethoxazole may not fully protect the HIVinfected host against disseminated T. gondii infection.
